The Role of Peptide YY (PYY)in Inhibiting Food Intake.

University of Copenhagen24 enrolled

Overview

12 obese subjects will receive peripheral administration of placebo and 4 escalating doses of PYY1-36 and another 12 obese subjects will receive peripheral administration of placebo and 4 escalating doses PYY3-36 on 5 different test days within one week. The patients will be tested in a single blinded dose escalating protocol. Measurements of appetite, ad libitum energy intake, blood pressure and blood sampling will be performed during the test day.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Obesity

Interventions

peripheral Peptide YY administrationDRUG

Eligibility

Sex: MALEMin age: 20 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Normal weight (BMI: 18-23 kg/m2) or 12 overweight/obese (BMI: 27-40 kg/m2) * Body weight fluctuations \< 5 kg over the past 2 months. * Blood pressure normal to mildly hypertensive(\<159/99 mm Hg) * Non-elite athletes and not planning to change physical activity during the study. Exclusion Criteria: * Any physiological or psychological illnesses that could influence the study results. * Regular use of medicine. * Smoking defined as \<1 cigarette per day. * Substance abuse or dependence. * Blood donation within the past 3 months before entering the study. * Drinking \>21 alcoholic units/week. * Food allergies. * Special diets (e.g. vegetarian) or dislikes to any of the foods served during the study.

Outcomes

Primary Outcomes

appetite

energy intake

Secondary Outcomes

Plasma PYY profile

Blood pressure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.